Increasing knowledge of HIV status in a country with high HIV testing coverage: Results from the Botswana Combination Prevention Project.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 06 06 2019
accepted: 27 10 2019
entrez: 26 11 2019
pubmed: 26 11 2019
medline: 24 3 2020
Statut: epublish

Résumé

Achieving widespread knowledge of HIV-positive status is a crucial step to reaching universal ART coverage, population level viral suppression, and ultimately epidemic control. We implemented a multi-modality HIV testing approach to identify 90% or greater of HIV-positive persons in the Botswana Combination Prevention Project (BCPP) intervention communities. BCPP is a cluster-randomized trial designed to evaluate the impact of combination prevention interventions on HIV incidence in 30 communities in Botswana. Community case finding and HIV testing that included home and targeted mobile testing were implemented in the 15 intervention communities. We described processes for identifying HIV-positive persons, uptake of HIV testing by age, gender and venue, characteristics of persons newly diagnosed through BCPP, and coverage of knowledge of status reached at the end of study. Of the 61,655 eligible adults assessed in home or mobile settings, 13,328 HIV-positive individuals, or 93% of the estimated 14,270 positive people in the communities were identified through BCPP. Knowledge of status increased by 25% over the course of the study with the greatest increases seen among men (37%) as compared to women (19%) and among youth aged 16-24 (77%) as compared to older age groups (21%). Although more men were tested through mobile than through home-based testing, higher rates of newly diagnosed HIV-positive men were found through home than mobile testing. Even when HIV testing coverage is high, additional gains can be made using a multi-modality HIV testing strategy to reach different sub-populations who are being missed by non-targeted program activities. Men and youth can be reached and will engage in community testing when services are brought to places they access routinely.

Identifiants

pubmed: 31765394
doi: 10.1371/journal.pone.0225076
pii: PONE-D-19-15524
pmc: PMC6876886
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0225076

Subventions

Organisme : NIAID NIH HHS
ID : K24 AI131928
Pays : United States
Organisme : CGH CDC HHS
ID : U01 GH000447
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001911
Pays : United States
Organisme : PEPFAR
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist, including the contractors from Northrup Grumman. Our adherence to PLOS ONE policies on sharing data and materials have not been altered.

Références

Lancet HIV. 2018 Mar;5(3):e116-e125
pubmed: 29199100
AIDS. 2016 Sep 10;30(14):2121-6
pubmed: 27258399
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
PLoS Med. 2016 Aug 09;13(8):e1002107
pubmed: 27504637
J Int AIDS Soc. 2015 May 29;18:19918
pubmed: 26028155
AIDS Behav. 2019 Apr;23(4):875-882
pubmed: 30673897
PLoS Med. 2011 Oct;8(10):e1001102
pubmed: 21990966
PLoS Med. 2012;9(12):e1001351
pubmed: 23226107
PLoS Med. 2013 Aug;10(8):e1001496
pubmed: 23966838
J Acquir Immune Defic Syndr. 2017 May 1;75 Suppl 1:S17-S26
pubmed: 28398993
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):e1-8
pubmed: 23714740
N Engl J Med. 2019 Jul 18;381(3):230-242
pubmed: 31314967
Lancet HIV. 2016 May;3(5):e212-20
pubmed: 27126488
Nature. 2015 Dec 3;528(7580):S77-85
pubmed: 26633769
J Int AIDS Soc. 2016 Feb 15;19(1):20673
pubmed: 26894388
JAMA. 2017 Jun 6;317(21):2196-2206
pubmed: 28586888
Lancet HIV. 2014 Nov;1(2):e68-e76
pubmed: 25601912
AIDS. 2017 Jul 17;31(11):1555-1564
pubmed: 28471766
AIDS. 2014 Sep 10;28(14):2133-45
pubmed: 25062091
Lancet HIV. 2016 Mar;3(3):e111-9
pubmed: 26939734
AIDS. 2017 Jul 01;31 Suppl 3:S221-S232
pubmed: 28665880
PLoS Med. 2017 May 2;14(5):e1002292
pubmed: 28464041
PLoS One. 2014 Jan 02;9(1):e84317
pubmed: 24392124

Auteurs

Mary Grace Alwano (MG)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Gaborone, Botswana.

Pamela Bachanas (P)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Atlanta, Georgia, United States of America.

Lisa Block (L)

Northrop Grumman, Atlanta, Georgia, United States of America.

Michelle Roland (M)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Gaborone, Botswana.

Baraedi Sento (B)

Tebelopele HIV Counseling and Testing Center, Gaborone, Botswana.

Stephanie Behel (S)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Atlanta, Georgia, United States of America.

Refeletswe Lebelonyane (R)

Botswana Ministry of Health and Wellness, Gaborone, Botswana.

Kathleen Wirth (K)

Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Faith Ussery (F)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Atlanta, Georgia, United States of America.

William Bapati (W)

Tebelopele HIV Counseling and Testing Center, Gaborone, Botswana.

Catherine Motswere-Chirwa (C)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Gaborone, Botswana.

William Abrams (W)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Gaborone, Botswana.

Gene Ussery (G)

Northrop Grumman, Atlanta, Georgia, United States of America.

James A Miller (JA)

Northrop Grumman, Atlanta, Georgia, United States of America.

Ebi Bile (E)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Gaborone, Botswana.

Peter Fonjungo (P)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Atlanta, Georgia, United States of America.

Agisanag Kgwadu (A)

Tebelopele HIV Counseling and Testing Center, Gaborone, Botswana.

Molly Pretorius Holme (MP)

Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Lisetta Del Castillo (L)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Gaborone, Botswana.

Tendani Gaolathe (T)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Kelebemang Leme (K)

Tebelopele HIV Counseling and Testing Center, Gaborone, Botswana.

Nokuthula Majingo (N)

Botswana Ministry of Health and Wellness, Gaborone, Botswana.

Shahin Lockman (S)

Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Brigham and Women's Hospital, Boston, Massachusetts, United States of America.

Joseph Makhema (J)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Naomi Bock (N)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Atlanta, Georgia, United States of America.

Janet Moore (J)

U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS, Atlanta, Georgia, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH